Sanofi said it plans to offer a monthly supply of insulin to some patients for $99. (CNBC) The discounted rate, which isn’t available to patients in the big federal health programs, was announced as insulin makers Sanofi, Eli Lilly and Novo Nordisk along with PBMs were set to testify Wednesday before a House committee. Lawmakers questioned why it took months of public outcry and bad press for Sanofi and Lilly to fairly price these medicines. (Bloomberg)

The Justice Department has charged Indivior with fraudulently marketing its opioid treatment, Suboxone Film. Indivior allegedly deceived doctors and payers about the safety of the drug while also connecting patients to doctors who prescribed the treatment at high rates. Indivior faces up to $3 billion in fines. (Endpoints)

Health and Human Services Secretary Alex Azar has said he regularly talks to President Donald Trump. Azar told STAT that he finds Trump to be “appropriately engaged” on health policies. Azar also spoke about the issue of drug pricing and how he handles policy proposals from both Democrats and Republicans. (STAT)

Walgreens is opening primary care clinics in five of its stores in Houston. The company is partnering with VillageMD to enhance the locations before the end of the year. Patients will be able to visit these Walgreens stores for the same reasons they go to their primary care doctor. (CNBC)

Gilead Sciences is reportedly laying off 20% of reps in its cardiopulmonary division. The move, affecting 150 sales people, comes in the wake of patent expiry for products Ranexa and Letairis, which combined for $1.7 billion in sales last year. Some employees have expressed concern that the company, under a recently appointed CEO, is struggling to find ways of growing revenue.  (STAT)

The deadline for submissions for the MM&M Awards has been extended to Wednesday, April 17. Also, register for the MM&M Transforming Healthcare Webcast taking place today at 1 pm EST for a sneak peek at the conference.